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Insertion and/or deletion mutations of the CALR gene have recently been demonstrated to be
the second most common driver mutations in the myeloproliferative neoplasms (MPNs) of
essential thrombocythemia (ET) and primary myelofibrosis (PMF). Given the diagnostic and
emerging prognostic significance of these mutations, in addition to the geographical hetero-
geneity reported, the incidence of CALR mutations was determined in an Irish cohort of
patients with MPNs with a view to incorporate this analysis into a prospective screening pro-
gram. A series of 202 patients with known or suspected ET and PMF were screened for the pres-
ence of CALR mutations. CALR mutations were detected in 58 patients. Type 1 and Type 1-like
deletion mutations were the most common (n = 40) followed by Type 2 and Type 2-like insertion
mutations (n = 17). The CALR mutation profile in Irish ET and PMF patients appears similar to
that in other European populations. Establishment of this mutational profile allows the intro-
duction of a rational, molecular diagnostic algorithm in cases of suspected ET and PMF that will
improve clinical management.
 2016 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
The classical Philadelphia chromosome-negative myelopro-
liferative neoplasms (MPNs) comprise the clinically and
pathologically related polycythemia vera (PV), essential
CALR mutations in Irish MPN patients 113thrombocythemia (ET), and primary myelofibrosis (PMF).
These diseases are characterized by an over production of
mature hematopoietic cells, extramedullary hematopoiesis,
and clinically by a tendency for thrombosis, hemorrhage,
and a potential to transform into acute leukemia. While
almost all PV patients are characterized by the Exon 14
JAK2 V617F and Exon 12 mutations, until recently, the only
known driver mutations of ET and PMF were the JAK2 V617F
and MPL Exon 10 mutations present in up to two-thirds of
patients. The landmark discovery of insertion and/or dele-
tion (indel) CALR Exon 9 mutations in 60–80% of JAK2
V617F- and MPL Exon 10-negative ET and PMF cases compels
the inclusion of CALR mutation analysis into the molecular
diagnostic algorithm for these MPNs. The two common CALR
mutations are the Type 1 52-bp deletion (p.L367fs*46) and
the Type 2 5-bp insertion (p.K385fs*47), which account for
more than 85% of indels [1,2] with most other mutations
being Type 1-like deletions or Type 2-like insertions. CALR
mutations are thought to exert their function by perturba-
tion of the intracellular Janus kinase/signal transducers
and activators of transcription (JAK/STAT) signaling path-
way by activation of MPL [3]. Molecular analysis of these
three driver mutation types is likely to be a major criterion
in the next revision of the World Health Organization classi-
fication of hematopoietic tumors [4]. Aside from their diag-
nostic importance, it is becoming increasingly apparent that
the different types of CALR mutations impart prognostic
information about thrombotic potential and leukemic trans-
formation [5–7]. Furthermore, some geographical hetero-
geneity exists in both the frequency and profile of CALR
mutations in ET and PMF when considering patients from
North America [8,9], Europe [1,2,10,11], Central and South
America [12,13], India [14], and Far East Asia [15,16].
Given the importance of CALR mutational analysis in the
diagnosis and prognosis of ET and PMF, the pattern of CALR
mutations was investigated in a cohort of adult Irish patients
with MPN. These data are likely to provide information about
how to efficiently incorporate CALR mutation analysis into a
prospective MPN molecular diagnostic service.
Materials and methods
A series of 202 confirmed and suspected MPN cases from two
large Irish hematology centers were subjected to retrospec-
tive CALR mutational analysis. None of the patients had evi-
dence of the JAK2 V617F mutation by allele-specific
polymerase chain reaction (PCR) [17]. CALR mutations were
detected in archival genomic DNA from peripheral bloodTable 1 Incidence of CALR Mutations in Irish MPN Patients
Type 1 Type 1 like
ET (n = 45) 26 5
PMF (n = 10) 8 0
Post-ET MF (n = 2) 1 0
MDS/MPN (n = 1) 0 0
Total 35 (60.3%) 5 (8.6%)
Note: ET = essential thrombocythemia; MDS/MPN = myelodysplastic/
myelofibrosis.(n = 190) or bone marrow (n = 12) by fluorescent PCR fol-
lowed by fragment length analysis. The CALR assay has been
previously demonstrated to possess a detection sensitivity
of 1% mutant allele burden [18].
Results
CALR mutations were detected in 58 patients (30 female
and 28 male) with a median age of 56 years (range,
25–86 years) in whom the diagnosis was ET (n = 45), PMF
(n = 10), post-ET myelofibrosis (n = 2), and myelodysplas-
tic/MPNs (n = 1). Type 1 CALR mutations were the most
prevalent, (n = 35) followed by Type 2 mutations (n = 16;
Table 1). Of the remaining seven cases, five had Type
1-like deletions, one had a Type 2-like insertion, and one
previously described patient harbored two mutated clones
[19]. The distribution of these mutations in the MPN sub-
types is given in Table 1.
Discussion
The description of CALR Exon 9 mutations in ET and PMF
patients has changed the molecular diagnostic algorithm
for MPN as they are now considered the second most com-
mon type of driver mutations in ET and PMF cases. Provision
of a confirmatory molecular diagnosis in a significantly
higher number of patients will enhance risk stratification
and allows for appropriate treatment: retrospective screen-
ing has demonstrated the efficacy of existing therapeutic
modalities such as interferon-alpha and JAK inhibitors in
CALR-mutated MPN patients [20,21].
Because of the diagnostic and emerging prognostic signif-
icance of these mutations, in addition to the geographical
and ethnic variation previously reported, the incidence of
CALR indels was investigated in a retrospective cohort of
Irish MPN patients to determine the existing mutational
spectrum. Given the near mutual exclusivity of the JAK2
V617F and CALR mutations but acknowledging the rarity of
these mutations co-existing in ET and a report of CALR
mutations in JAK2-negative PV [22–24], this retrospective
study was limited to known and suspected ET and PMF
patients in whom the JAK2 V617F was previously unde-
tected. Although a number of methodological approaches
exist to detect CALR mutations [25], the sensitivity of the
fragment length analysis used in this study was deemed suf-
ficient to detect clinically relevant mutations: CALR mutant
allele burdens are usually much higher [26].Type 2 Type 2 like Other
12 1 1
2 0 0
1 0 0
1 0 0
16 (27.6%) 1 (1.7%) 1 (1.7%)
myeloproliferative neoplasm; MF = myelofibrosis; PMF = primary
114 K. Haslam et al.The CALR mutation profile and frequency in this cohort
of Irish patients are broadly in line with that of other series
from Europe and North America, with Type 1 and Type 1-like
mutations being more prevalent than Type 2 and Type 2-like
in both ET and PMF patients. Establishing this mutational
profile allows considered incorporation of CALR mutation
testing into a prospective MPN molecular diagnostic algo-
rithm so as to optimize the number of patients who would
benefit from such testing within existing laboratory
resources. Given the previously described variability in
requesting JAK2 V617F analysis within this country [27],
together with the knowledge of the near absence of CALR
mutations in splanchnic, cerebral, and other cases of unpro-
voked venous thrombosis [28–30], limiting testing to those
patients with suspected ET and PMF appears judicious.
In conclusion, the incidence and spectrum of CALR
mutations in Irish MPN patients are similar to those of
other European cohorts confirming these driver mutations
as the second most frequently observed in ET and PMF.
This knowledge allows the effective incorporation of CALR
mutation analysis into a prospective testing algorithm, thus
enabling an enhanced diagnosis and improved clinical
management.
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